Syngeneic Mouse Models
Syngeneic mouse models represent one of the first steps needed to determine the efficacy of your novel immunotherapies in an in vivo model with functional immune system
Syngeneic mouse models are established from immortalized murine cancer cells originating from inbred mouse strains that are implanted and grown in genetically identical strains. Avoiding the need to use immunocompromised mice, this approach allows you to study your novel immunotherapy’s efficacy in a mouse model that combines tumor microenvironment interactions with a fully functional immune system.
Therefore, experts at InnoSer recommend the use of syngeneic rodent models (mice or rats) as a first step to evaluate the efficacy of your novel immunotherapy approaches (vaccines, mRNA-based therapeutics, immune checkpoint inhibitors, antibody-drug conjugates, (stem) cell therapy such as CAR-T cell therapy, NK cell therapy, etc., as well as classical anti-tumoral compounds (chemotherapy, radiotherapy). Accordingly, syngeneic mouse models represent an easy-to-use, relatively inexpensive mouse model with short study timelines (2-4 weeks), offering reproducible immune response results. However, for more advanced studies, InnoSer’s experts recommend working with humanized mouse models.
Developing new, safe, and efficacious anticancer therapies is an extremely intricate process. As a preclinical oncology contract research organization (CRO), InnoSer partners with you to help you navigate the complexities of this research area.
Scientists at InnoSer collaborate with you to develop the most optimal study design to help answer your research questions most cost-effectively. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo oncology drug development portfolio.
Services with Syngeneic Mouse from InnoSer:
- Available as subcutaneous or orthotopic models (fluorescently labeled rodent cell lines or followed-up via ultrasound).
- Both murine and rat cell lines are available.
- Complementary immuno-oncology in vitro assays and PK/PD profiling services.
Find the right model for you.
Compare our model capabilities and discover which of our oncology platforms suits your research needs
Key Readouts in Syngeneic Mouse Models:
Test the efficacy of your treatments using syngeneic mouse models with the following readouts:
- Response to treatment (tumor growth kinetics, body weight, clinical signs, survival analyses)
- In vivo imaging (bioluminescence imaging, ultrasound)
- Isolation of tumors and other relevant organs for histopathology analyses (biomarker analyses)
- Immune cell profiling (multi-panel flow cytometry analyses with up to 12 markers; lymphoid, myeloid panels)
- Blood sampling for biomarker analyses (MSD)
Example data featuring syngeneic mouse models:
Tumor growth curve data from the 4T1 (breast cancer cell line) syngeneic mouse model.
Following initial cell culturing, murine breast cancer cells (4T1 mouse breast cell line) were injected orthotopically (directly into the mammary fat pad) of BALB/C mice. This mouse model is available at InnoSer both as an (A) subcutaneous (4T1) whereby tumor growth is followed via calipers and (B) orthotopic mouse model (4T1-luc) whereby tumor growth is followed via bioluminescent imaging. The model is validated with standard-of-care treatments doxorubicin and gemcitabine.
Tumor growth curve data from the PanO2 (pancreatic cancer cell line) syngeneic mouse model.
Following initial cell culturing, murine pancreatic cancer cells (PanO2 cell line) were injected subcutaneously into the left flank of C57BL/6 mice. Model is validated with standard-of-care treatment gemcitabine (tested at different concentrations).
Tumor growth curve data from the MC38 (colorectal carcinoma) syngeneic mouse model.
Following initial cell culturing, murine colorectal carcinoma cells (MC38 cell line) were injected into the left flank of C57BL/6 mice. The MC38 colorectal carcinoma syngeneic mouse model is available at InnoSer both as (A) subcutaneous and (B) orthotopic model. The model is validated with checkpoint inhibitor anti-PD-1.
Tumor growth curve data from the Renca (renal cell carcinoma) syngeneic mouse model.
Following initial cell culturing, murine renal cell carcinoma cells (Renca cell line) were injected into the left flank of C57BL/6 mice. The renal cell carcinoma Renca syngeneic mouse model is available at InnoSer both as a (A) subcutaneous model and orthotopic (B-C) model. The model is validated with standard-of-care treatment Doxorubicin (different dosages tested). Compared to healthy kidneys (B), kidneys of mice injected with Renca cells (C) lead to increase in total kidney volume and development of lesions which can be longitudinally imaged and quantified.
Related model options
Oncology Platform Overview
Highly relevant oncology CRO services to facilitate preclinical drug development.
Cell line-derived Xenograft (CDX) Mouse Models
CDX models represent one of the first steps to evaluate the efficacy using in vivo models of human cancer.
Patient-derived Xenograft (PDX) Mouse Models
Recapitulate the tumor and patient heterogeneity using patient-derived xenograft (PDX) mouse models.
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Ready to work with a CRO that’s as committed as you are?
Join us in delivering impactful studies that bring therapies to patients sooner.
info@innoserlaboratories.com